Alphatec (ATEC) Stock Price, News & Analysis

Company Overview

Alphatec Holdings, Inc. (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market. Alphatec has introduced technologies such as the iGAINS® implant for adjustable anatomical fit and the SONICanchor® fixation system to enhance implant stability. Its proprietary OsteoStrand™ biologic portfolio supports bone growth through versatile carrier options, reflecting the company’s emphasis on combining mechanical and biological approaches to fusion.

Alphatec serves a broad patient base across North America, with expanding footprints in Europe, Latin America and select Asia-Pacific markets. The company collaborates with hospitals, ambulatory surgery centers and specialty spine centers, providing training and support services to surgeons adopting its technologies. Regional distribution agreements and direct sales channels aim to ensure consistent product availability and clinical support worldwide.

Under the leadership of President and Chief Executive Officer William J. Dickerson, Alphatec has pursued strategic partnerships and targeted acquisitions to diversify its technology pipeline. The senior management team brings experience in medical device commercialization, regulatory affairs and global operations. With ongoing investments in research and development, Alphatec continues to advance its next-generation systems and digital planning tools to address evolving surgical needs in spine care.

Key Stats

• Today's Range: $9.08 to $9.51
• 50-Day Range: $8.06 to $10.35
• 52-Week Range: $6.82 to $23.29
• Volume: 1.58 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $1.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.40
• Consensus Rating: Moderate Buy

Alphatec Stock Analysis - MarketRank™

Alphatec scored higher than 60% of companies evaluated by MarketBeat, and ranked 332nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alphatec has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alphatec has a consensus price target of $17.40, representing about 84.1% upside from its current price of $9.45.

Amount of Analyst Coverage

Alphatec has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alphatec are expected to grow in the coming year, from ($0.45) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alphatec is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alphatec is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.20% of the float of Alphatec has been sold short.

Short Interest Ratio / Days to Cover

Alphatec has a short interest ratio ("days to cover") of 4.81.

Change versus previous month

Short interest in Alphatec has recently decreased by 1.15%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alphatec does not currently pay a dividend.

Dividend Growth

Alphatec does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

13 people have searched for ATEC on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alphatec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alphatec insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,282.00 in company stock.

Percentage Held by Insiders

13.48% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.35% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/05/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/09/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATEC
• CIK: 1350653
• Web: www.atecspine.com
• Phone: (760) 431-9286
• Fax: 800-922-1356
• Employees: 700
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Alphatec: $17.40
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +84.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.36 million
• Net Margins: -13.49%
• Pretax Margin: -13.46%
• Return on Equity: -6,752.24%
• Return on Assets: -13.88%

Debt

• Debt-to-Equity Ratio: 40.35
• Current Ratio: 1.89
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $764.16 million
• Price / Sales: 1.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.08) per share
• Price / Book: -118.13

Miscellaneous

• Outstanding Shares: 154,450,000
• Free Float: 133,631,000
• Market Cap: $1.46 billion
• Optionable: Optionable
• Beta: 0.85